Why? Firstly, Aaron and Doan are still working with us on the clinical trial. Secondly, they are still working with bisantrene, just on their own.
Finally, there are dozens of drugs that offer cardioprotection including many that are approved for use in humans and have been around for decades. The problem is none of them are used by doctors. The thing that makes bisantrene special is not that it is cardioprotective, but that it is cardioprotective and anti-cancer at the same time. This is what makes bisantrene so special.
RAC media coverage, page-1869
-
- There are more pages in this discussion • 449 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.055(3.79%) |
Mkt cap ! $237.8M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.45 | $1.33 | $213.7K | 155.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 55 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 7167 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |